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Primary chronic venous disorders, which according to the CEAP classification are those not associated with an identifiable
mechanism of venous dysfunction, are among the most common in Western populations. Varicose veins without skin
changes are present in about 20% of the population while active ulcers may be present in as many as 0.5%. Primary venous
disorders are thought to arise from intrinsic structural and biochemical abnormalities of the vein wall. Advanced cases
may be associated with skin changes and ulceration arising from extravasation of macromolecules and red blood cells
leading to endothelial cell activation, leukocyte diapedesis, and altered tissue remodeling with intense collagen
deposition.
Laboratory evaluation of patients with primary venous disorders includes venous duplex ultrasonography performed in
the upright position, occasionally supplemented with plethysmography and, when deep venous reconstruction is
contemplated, ascending and descending venography. Primary venous disease is most often associated with truncal
saphenous insufficiency. Although historically treated with stripping of the saphenous vein and interruption and removal
of major tributary and perforating veins, a variety of endovenous techniques are now available to ablate the saphenous
veins and have generally been demonstrated to be safe and less morbid than traditional procedures. Sclerotherapy also has
an important role in the management of telangiectasias; primary, residual, or recurrent varicosities without connection to
incompetent venous trunks; and congenital venous malformations. The introduction of ultrasound guided foam
sclerotherapy has broadened potential indications to include treatment of the main saphenous trunks, varicose tributar-
ies, and perforating veins. Surgical repair of incompetent deep venous valves has been reported to be an effective
procedure in nonrandomized series, but appropriate case selection is critical to successful outcomes. (J Vasc Surg 2007;
46:54S-67S.)INTRODUCTION
Chronic venous disorders (CVD) include a spectrum of
clinical presentations ranging from uncomplicated telangi-
ectasias and varicose veins to venous ulceration. Chronic
venous insufficiency (CVI) usually refers more specifically
to the spectrum of skin changes associated with sustained
venous hypertension. Manifestations of chronic venous
disorders may result from primary venous insufficiency or
be secondary to other processes, primarily acute deep ve-
nous thrombosis (DVT). This manuscript addresses the
current state of knowledge with respect to primary chronic
venous disorders.
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54SLower extremity venous disease is common and in
the United States, the number of afflicted individuals is
equivalent to the entire population of the states of Texas,
Florida, and Connecticut. Regardless of the underlying
etiology, CVI is the seventh leading cause of chronic
debilitating disease in the United States (U.S.).1 Ten to
35% of the U.S. adult population has some form of CVI.2
In industrialized nations, up to 1.5% of people will suffer
from venous ulceration and in patients 65 years and
older, the incidence increases to 4%.1,3 Currently, more
than 500,000 people suffer from venous stasis ulcers.1,4
The lack of effective therapies and the recurrent nature of
the disease place a heavy burden on the U.S. healthcare
system. The population-based costs in the U.S. for treat-
ment of CVI and venous ulcer care has been estimated at
over one billion dollars a year.5,6 The high incidence and
increasing cost of CVI care has renewed interest in this
disease process and much has been learned in the past
decade.
Great progress has been made in understanding the
pathophysiology and hemodynamics of chronic venous dis-
orders. In primary chronic venous disease, this has led to a
variety of new management tools that are frequently less
invasive and more cosmetically acceptable than traditional
extensive vein stripping.
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DISORDERS
In order to standardize the reporting and treatment of
the diverse manifestations of chronic venous disorders, a
comprehensive classification system (CEAP) has been de-
veloped to allow uniform diagnosis and comparison of
patient populations. Created by an international ad hoc
committee of the American Venous Forum (AVF) in
1994,7 it has been promulgated throughout the world and
is now the accepted standard for classifying chronic venous
disorders. The fundamentals of the CEAP classification
include a description of the clinical class (C) based upon
objective signs; the etiology (E); the anatomical (A) distri-
bution of reflux and obstruction in the superficial, deep,
and perforating veins; and the underlying pathophysiology
(P), whether due to reflux or obstruction.7 Seven clinical
categories are recognized including limbs without venous
disease (class 0) and those with telangiectasias (class 1),
varicose veins (class 2), edema (class 3), skin changes with-
out ulceration (class 4a and 4b), healed ulcers (class 5), and
active ulcers (class 6). (Table I) The underlying etiology
can further be classified as congenital, primary, or second-
ary. Primary venous disorders are not associated with an
identifiable mechanism of venous dysfunction. In contrast,
secondary venous disorders result from an anteceded event,
usually an episode of acute DVT. As discussed below, the
Table I. CEAP classification of chronic venous disease
Clinical classification
C0: no visible or palpable signs of venous disease
C1: telangiectasies or reticular veins
C2: varicose veins
C3: edema
C4a: pigmentation or eczema
C4b: lipodermatosclerosis or atrophic blanche
C5: healed venous ulcer
C6: active venous ulcer
S: symptomatic, including ache, pain, tightness, skin irritation,
heaviness, and muscle cramps, and other complaints
attributable to venous dysfunction
A: Asymptomatic
Etiologic classification
Ec: congenital
Ep: primary
Es: secondary (post-thrombotic)
En: no venous cause identified
Anatomic classification
As: superficial veins
Ap: perforator veins
Ad: deep veins
An: no venous location identified
Pathophysiologic
Pr: reflux
Po: obstruction
Pr,o: reflux and obstruction
Pn: no venous pathophysiology identifiable
Adapted from Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the
CEAP classification of chronic venous disease. J Vasc Surg 2004;40:
1248-52.8underlying pathophysiology, whether due to reflux or ob-struction, can be further localized to precise lower extrem-
ity venous segments (Table II).
Designed to be a document that would evolve over
time, CEAP underwent its first official review and revision
by an international panel under the auspices of the AVF in
2004.8 The revised document retains the basic CEAP cat-
egories, but improves the underlying details including ter-
minology; divides the C4 class into a and b categories; and
adds several descriptors to the E, A, and P categories. A new
severity scoring system was adopted to replace the origi-
nal.9 Important details and conventions related to writing
the CEAP classification, dating it, and denoting the diag-
nostic method used for the classification were defined.
Furthermore, to encourage wider usage among clini-
cians, an abbreviated or “basic CEAP” was adopted as an
alternative to the comprehensive CEAP. The basic CEAP
eliminates some of the details of the full CEAP, as illus-
trated by the following example:
A patient with pain, varicose veins, and lipodermato-
sclerosis in whom duplex ultrasonography confirms pri-
mary reflux of the great saphenous vein and incompetent
perforators in the calf would have the following “advanced”
CEAP:
C2,4b,S, Ep, As,p, Pr2,3,18
The new “basic CEAP” would be:
C4b,S, Ep, As,p, Pr
in which the clinical class is denoted only by the highest
number (4b) and precise localization of segmental reflux is
eliminated. The ultimate simplification of using only the
highest clinical class (C4b) was discarded as inadequate for
scientific interchange.
In addition to the classification itself, the date of the
Table II. Eighteen named venous segments (with
number designations)
Superficial veins
(1) Telangiectasias or reticular veins
(2) Great saphenous vein above knee
(3) Great saphenous vein below knee
(4) Small saphenous vein
(5) Nonsaphenous veins
Deep veins
(6) Inferior vena cava
(7) Common iliac vein
(8) Internal iliac vein
(9) External iliac vein
(10) Pelvic: gonadal, broad ligament veins, other
(11) Common femoral vein
(12) Deep femoral vein
(13) Femoral vein
(14) Popliteal vein
(15) Crural: anterior tibial, posterior tibial, peroneal veins (all
paired)
(16) Muscular: gastrocnemial, soleal veins, other
Perforating veins
(17) Thigh
(18) Calf
Adapted from Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the
CEAP classification of chronic venous disease. J Vasc Surg 2004: 40;
1248-1252. 8classification and the “Level” of diagnosis (L1 office, LII
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should be added, as follows:
C2,4b,S, Ep, As,p, Pr (2003-08-21, LII)
EPIDEMIOLOGY OF CHRONIC VENOUS
DISORDERS
Early epidemiologic studies
Several epidemiological studies of chronic venous dis-
ease in various countries have been performed over the last
several decades. Most of these have focused on varicose
veins.10-17 Earlier studies reported varicose veins to be
present in 1% to 73% of females and 2% to 56% of males.
The prevalence of CVI in these studies ranges from 1% to
40% in females and 1% to 17% in males.10 However, the
results have varied with geography and study methods.
Varicose veins have a prevalence of 25% to 33% and 10% to
20% in Western females and males, respectively.10,11,15,17
The annual incidence of varicose veins in the Framingham
study was 2.6% in women and 1.9% in men.18 The preva-
lence of skin changes varied between 3% and 13% in the
population. The prevalence of active and healed ulcers
varied between 1% and 2.7%. Established risk factors for
chronic venous disease include older age, family history,
female gender, multiple pregnancies, standing occupation,
and obesity in females.10,11,14,18
However, the early data has several limitations includ-
ing the use of different definitions for varicose veins and
CVI, inclusion of different age groups, and frequently a
failure to include a random sample of the general popula-
tion. As the prevalence of chronic venous disease increases
with age and is higher in females, the data has to be adjusted
for age and gender. Furthermore, many studies have relied
on amnestic data from questionnaires rather than clinical
and duplex evaluation. Only a few recent studies have used
the CEAP classification.19-21
Epidemiologic studies based on the CEAP
classification
In recent years, three studies have been published based
Table III. Prevalence of C0-C6 (CEAP) in the Bonn21, P
Bonn Vein Study
Design Random sample
Survey General population
Investigators Phlebologists
CVI definition C3 – C6
Participants 3072 
Males 1350
Females 1722
Classification All (%) Male (%) Female (%
C0 9.6 13.6 6.4
C1 59.1 58.4 59.5
C2 14.3 12.4 15.8
C3 13.4 11.6 14.9
C4 2.9 3.1 2.7
C5 0.6 0.6 0.6
C6 0.1 0.1 0.1on the CEAP classification.22 They differ with respect tomode of recruitment of the study population, age, and
methods of investigation19,20,22(Table III).
The Bonn Vein Study enrolled 3072 (1722 women,
1350 men) participants, 18 to 79 years of age, from a
random sample of the population registers of Bonn and two
rural townships.21 All participants completed a standard-
ized questionnaire and underwent a clinical and duplex
examination by four trained phlebologists. The complete
CEAP was used for classification.
Leg complaints consistent with venous disease (leg
heaviness, subjective swelling) were present in 49.1% and
62.1% of German males and females, respectively. With
respect to CEAP-classification, only 9.6% of the population
(13.6% men, 6.4% women) showed no signs of venous
disorders (CO); 59.1% (58.4 men, 59.5% women) showed
only telangiectasias or reticular veins (C1). Varicose veins
without edema or skin changes (C2) where present in
14.3% (12.4%men, 15.8% women); pretibial pitting edema
(C3) in 13.4% (11.6% men, 14.9% women); skin changes
(C4) including eczema, pigmentation, or lipodermatoscle-
rosis in 2.9% (3.1% men, 2.7% women); and healed (C5) or
active (C6) ulceration in 0.6% and 0.1%, respectively (Table
III). The prevalence of stages C2 to C6 disease increased
with age. Only in stages C2 and C3 was the prevalence
significantly higher in females. The urban population
showed a higher frequency of CVI (C3 to C6). In a
multivariate analysis adjusted for age and region of living,
risk factors for varicose veins included older age, female
gender, pregnancy and obesity in women. Risk factors for
CVI were older age, obesity, and urban residence.
In a cross-sectional, multicenter Polish study,20 40,095
adults were interviewed and clinically evaluated by 803
participating primary care physicians. Patients were classi-
fied by highest CEAP clinical severity and CVI was defined
as stages C1 to C6. Leg complaints were present in 81% in
patients with varicose veins and 35% of the varicose-free
participants. C0 was found in 51.1% of the population, C1
in 16.5%, C2 in 21.8%, C3 in 4.5%, C4 in 4.6%, C5 in 1.0%,
and C6 in 0.5%. Risk factors for CVI and varicose veins
20 and French19 Studies
Polish Study French Study
Cross-sectional Cross-sectional
Consecutive primary
Care patients
Telephone lists
Primary care physicians Vascular physicians
C1 – C6 Trophic skin changes
40,095 409
6404 277
33691 132
All (%) Male (%) Female (%)
51.5
16.5
21.8 23.7 46.3
4.5 1.1 2.2
4.6 4.0 2.1
1.0 1.4 0.7
0.5 0.0 0.0olish
)were similar.
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tion of patients enrolled in a study of Raynaud’s phenom-
enon.19 All patients were evaluated using a standardized
questionnaire and examination by a vascular specialist. C0
or C1 disease was present in 48.7% of patients; C2 was
present in 23.7% and 46.3% of males and females, respec-
tively; C3 was found in 1.1% and 2.2%, respectively; and C4
in 4.0% of the men and 2.1% of the women. Healed ulcers
were found in 1.4% of the males and 0.7% of the females.
No active ulcers were identified in this study. The main risk
factors for varicose veins included family history, advanced
age, pregnancy, and height in women and exercise less than
once a week in men.
SUMMARY
Chronic venous disorders are among the most frequent
in western populations. Venous symptoms such as heavi-
ness of the legs, swelling, and pain during standing are
correspondingly frequent complaints. Although there are
differences between recent studies, some generalizations
are possible. Varicose veins without skin changes are
present in about 20% of the general population, slightly
more frequent in women. The exact prevalence of C3
remains uncertain due to lack of standardized definition.
Only the Bonn Vein Study precisely defined pitting edema.
This may have caused differences in the prevalence of C3,
varying between 1.1% and 14.9%. The prevalence of more
advanced CVI in the studies is similar – the prevalence of
signs such as eczema, pigmentation, and lipodermatoscle-
rosis or venous ulceration reaching about 5% in men and
women. C4 varied between 2.1% in France and 4.6% in
Poland. The highest prevalence of healed ulcers was found
in French men (1.4%) and the lowest in the German pop-
ulation (0.6%). Active venous ulcers were found in between
0.0% and 0.5% of the population. The main risk factors for
varicose veins are advanced age, female gender, pregnancy,
and family history. Obesity seems to play a more important
role in CVI than in varicose veins.19-21
PATHOPHYSIOLOGY OF CHRONIC VENOUS
DISORDERS
Varicose veins
Despite advances in our understanding of varicose
veins, the underlying etiology remains uncertain. Early
theories presumed that varicose veins arose from the effects
of valvular incompetence and venous hypertension and
arose in a descending fashion from valvular incompetence
at the saphenofemoral or saphenopopliteal junction. Un-
fortunately, there is little evidence of a constitutive valvular
abnormality in primary venous disease and these theories
cannot explain why truncal varicosities are often found
below competent valves, why normal valves are often seen
between those exhibiting varices, or why dilation often
precedes valvular incompetence.23,24 Rather than being
initiated at the saphenofemoral junction, both detailed
studies of surgical specimens and ultrasound observation
suggest that primary valvular incompetence is a multicen-tric process that develops simultaneously in discontinuous
venous segments.25
Recent theories have focused on intrinsic structural and
biochemical abnormalities of the vein wall, hypothesizing
that varicose veins develop because of underlying connec-
tive tissue defects and altered venous tone.26-28 Varicose
veins demonstrate diverse histologic abnormalities, includ-
ing irregular thickening of the intima, fibrosis between the
intima and adventitia, atrophy and disruption of elastic
fibers, thickening of individual collagen fibers, and disorga-
nization of the muscular layers that are heterogeneously
distributed throughout the great saphenous vein and its
tributaries.29-34
The histological changes suggest that varicose veins
have reduced contractility and compliance. Varicose saphe-
nous veins show an increased collagen and reduced elastin
content.35 Saphenous smooth muscle content, as well as
total protein content, is reduced and effective contraction
may be further compromised by fragmentation of the mus-
cle layers.33,36 Similar findings in limbs without varices but
at risk for their development and in the forearm veins of
varicose vein patients suggest that abnormalities in vein wall
architecture precede the development of both overt vari-
cosities and valvular incompetence.26,28
It remains unclear whether these structural changes
are primary or result from other pathologic processes.
Proposed mechanisms have included hypoxia induced
endothelial changes; downregulated apoptosis; changes
in enzyme activity associated with decreased energy me-
tabolism and increased lysosomal activity; and underly-
ing defects in venous tone associated with a loss of
vascular reactivity.29,33,37-39
Chronic venous insufficiency
Microscopic alterations. Over the past century, nu-
merous theories regarding the etiology of venous stasis
ulceration have been proposed. The earlier theories are of
historical interest only and recent attention has focused on
inflammation and the events regulating it.40 Our current
knowledge indicates that venous hypertension causes ex-
travasation of macromolecules (ie, fibrinogen and 2-mac-
roglobulin) and red blood cells (RBCs) into the dermal
interstitium resulting in a persistent or chronic injury stim-
ulus.40-44 RBC degradation products and interstitial pro-
tein extravasation are potent chemoattractants and presum-
ably represent the initial underlying chronic inflammatory
signal responsible for leukocyte recruitment. It has been
assumed that these cytochemical events are responsible for
the increased expression of ICAM-1 (intercellular adhesion
molecule-1) on endothelial cells of microcirculatory ex-
change vessels observed in CVI dermal biopsies.45 ICAM-1
is the activation dependent adhesion molecule utilized by
macrophages and lymphocytes for diapedesis. Both these
cells have been observed by immunohistochemistry in the
interstitium of dermal biopsies.45 However, a recent mor-
phometric assessment of the dermal microcirculation iden-
tified macrophages and mast cells only and questioned the
role of lymphocytes in CVI dermal pathology.46 The exact
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however, the presence of mast cells suggests a role in
cytokine activation, tissue remodeling, or ulcer formation.
Extracellular matrix (ECM) alterations. Once leu-
kocytes have migrated to the extracellular space, they local-
ize around capillaries and postcapillary venules. The
perivascular space is surrounded by extracellular matrix
(ECM) proteins, forming a perivascular “cuff”.41,43-45,47
This perivascular “cuff” and the accompanying collagen
deposition are the sine qua non of CVI tissue damage. The
role of the cuff and its cell of origin are not completely
understood. The cuff was once thought to be a barrier to
oxygen and nutrient diffusion. However, recent evidence
suggests that cuff formation is an attempt to maintain
vascular architecture in response to an increasedmechanical
load.48 Immunohistochemical analyses have demonstrated
transforming growth factor-1 (TGF-1) and 2-macro-
globulin in the cuff interstices.43 It has been suggested that
these “trapped” molecules are abnormally distributed in
the dermis leading to altered tissue remodeling and fibrosis.
Cytokine regulation and tissue fibrosis. Leukocyte
recruitment, ECM alterations and tissue fibrosis are char-
acteristic of chronic inflammatory diseases caused by alter-
ations in TGF-1 gene expression and protein production.
TGF-1 has been demonstrated to be present in pathologic
amounts in the dermis of patients with class 4, 5 and 6 CVI.
The intense tissue fibrosis clearly is caused by the excess
amounts of TGF-1. Whether or not TGF-1is involved in
ulcer development is currently unclear. Other cytokines
such as vascular endothelial growth factor (VEGF) and
platelet derived growth factor (PDGF) have been identified
in dermal biopsies of CVI patients but their role in the
pathophysiology of the disease is unclear.
Role of matrix metalloproteinases (MMPs) and
their inhibitors in venous ulcer healing. The signaling
event responsible for the development of a venous ulcer and
the mechanisms responsible for prolonged wound healing
are poorly understood.Wound healing is an orderly process
that involves inflammation, re-epithelialization, matrix
deposition, and tissue remodeling. Tissue remodeling and
matrix deposition are processes controlled by MMPs and
tissue inhibitors of matrix metalloproteinases (TIMPs). In
general, MMPs and TIMPs are not constitutively ex-
pressed, but are induced in response to exogenous signals
such as various cytokines or growth factors, cell-matrix
interactions and altered cell-cell contacts. TGF-1 is a
potent inducer of TIMP-1 and inhibitor of MMP-1. Sev-
eral studies have demonstrated that prolonged and contin-
uous TGF-1 production causes tissue fibrosis by stimulat-
ing ECM production and inhibiting degradation through
its effects on MMP and TIMP. In patients with active
ulcers, increases in MMP activity from ulcer exudates and
decreased expression of TIMP-1 in keratinocytes have been
reported.49 These observations suggest that excessive pro-
teolysis may be responsible for the decreased healing rates
seen with venous stasis ulcers.
Summary. CVI is the result of venous hypertension
caused by venous valvular incompetence. Prolonged expo-sure to venous hypertension causes extravasation of macro-
molecule and RBCs, which in turn leads to microvascular
endothelial cell activation, leukocyte diapedesis, ECM al-
terations, and intense collagen deposition. The changes in
the dermal microcirculation and interstitium are partially
mediated by increased levels of TGF-1. TGF-1 causes
increased ECM and collagen production and altered tissue
remodeling by affecting MMP and TIMP production. The
exact cause of ulcer formation remains unknown, however,
the presence of mast cells suggests that they may play an
important regulatory role.
DIAGNOSTIC EVALUATION OF CHRONIC
VENOUS DISEASE
The diagnostic evaluation of chronic venous disease has
advanced from a clinical impression based upon physical
examination to an objective image-based process similar to
that followed for arterial disease. It is comprised of clinical
and laboratory elements that address the presenting fea-
tures, underlying etiology, distribution, and mechanism of
disease. In doing so, it provides the essential elements of the
CEAP classification.
The complete diagnosis includes both clinical and lab-
oratory elements and can be achieved with a single office
visit and a noninvasive vascular laboratory examination that
consists of a focused hand-held Doppler examination and
an erect venous duplex scan supplemented when necessary
by plethysmography. In the minority of venous cases in
which deep venous reconstruction is considered, a more
invasive examination with ascending and descending
venography or venous pressure studies may be needed.
Since the ultrasound examination is painless, safe, and
affordable, this objective image-based workup of CVD is
practical and constitutes the standard of practice.
Clinical evaluation
The clinical evaluation determines the nature and the
severity of the underlying venous problem and its impact on
the patient’s quality of life. In this phase, the presenting
symptoms and signs are assessed and assigned to a hierarchy
of categories including telangiectasias, varicose veins, ve-
nous edema, skin changes, and ulceration. The disease
classification,8,50 severity, and effect on the patient’s quality
of life determine the degree of investigation required to
guide treatment.
Laboratory evaluation
The laboratory evaluation of chronic venous disease
defines the cause of the problem as congenital, primary, or
secondary; the anatomic location of the problem in the
superficial, perforator, or deep systems; and the pathophys-
iologic mechanism as pure reflux, reflux with obstruction,
or dominant obstruction. The pathophysiologic mecha-
nisms are localized to 18 defined segments from the calf to
the inferior vena cava (IVC).
Duplex ultrasonography. Duplex ultrasonography,
using an erect venous reflux protocol, is an essential com-
ponent of the evaluation of chronic venous disorders. The
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differs substantially from that used to exclude deep venous
thrombosis. It is optimally performed in the standing posi-
tion and includes an assessment of both reflux and obstruc-
tion in the deep, superficial, and perforating veins from the
IVC to the calf veins. Based upon the clinical evaluation, a
more or less detailed scan may be adequate. When the
problem is limited to telangiectasias (clinical class 1), ultra-
sound scanning of the deep and perforator veins is of
minimal importance and can be omitted or substituted with
a continuous wave Doppler examination. For class 2 (vari-
cose veins) and 3 (venous edema) disease, a complete scan
is warranted to identify reflux and obstruction in the deep
and perforating systems. In advanced venous insufficiency
(clinical classes 4 to 6 and selected class 3), a full and
detailed examination of all of the segments is necessary
when the treatment alternatives might include interven-
tions involving perforator or deep veins. If intervention has
been ruled out (eg, reasons of risk or inactivity) the utility of
a full scan is limited to assisting with prognosis or intensity
of medical management.
Duplex ultrasonography is required for determination
of the etiologic, anatomic, and pathophysiologic elements
of the CEAP classification. It is possible to distinguish
congenital, primary and secondary causes of CVD in the
majority of cases. The valvular reflux and varicose changes
in primary disease are readily distinguished from the lumi-
nal scarring and obstructive pattern of post-thrombotic
disease, even though the post-thrombotic vein may also
show significant reflux. Problems can arise in differentiating
primary from completely recanalized post-thrombotic dis-
ease, which may also present as pure reflux. Anatomically,
although the identification of reflux and obstruction in the
superficial and deep veins is accurate, some aspects of the
perforator examination are controversial. Although most
perforating veins are not visualized, ultrasonic detection of
abnormal perforators rivals or exceeds venographic meth-
ods.51 Limitations are that the assignment of reflux and
obstruction to precise venous segments may be both oper-
ator- and equipment-dependent, and detection of subtle
degrees of post-thrombotic partial obstruction and early
valve reflux may be difficult.
Physiologic noninvasive tests. In contrast to the pre-
cise segmental information provided by ultrasound, mea-
surement of volume or pressure changes with guided ma-
nipulation of the extremity provides reliable global
information about venous function. The quantitative esti-
mate of venous reflux provided by air plethysmography
(APG), specifically the VFI, has proven useful pre- and
postoperatively in assessing the results of therapy.52,53
However, some limitations of these physiologic measure-
ments have been expressed.54,55 Pressure measurements
are occasionally necessary in the evaluation of obstruction
prior to or following deep vein reconstruction.56 The prac-
tical application of the physiologic tests has been dimin-
ished by the widespread availability of duplex ultrasonog-
raphy and treatment decisions seldom require these tests.Venography. Although largely replaced by ultra-
sound scanning for initial definitive diagnosis, venography
retains a critical role in the evaluation of advanced CVI
prior to and perhaps after venous reconstruction.57 As-
cending venography provides an overall anatomic map of
the lower extremity veins and pathways of venous return.
Manipulation of patient position from horizontal to verti-
cal, combined with tourniquets at various levels, can reveal
important physiologic data about partial and complete
segmental obstruction. Descending venography is the stan-
dard for analyzing sites of venous valves, distinguishing
primary valve disease from secondary, and estimating sever-
ity of reflux. It may also provide further information regard-
ing patent venous channels in obstructive disease. Com-
puted tomographic (CT) and magnetic resonance (MR)
venography will likely have an increasingly important role
in the future.
SURGICAL TREATMENT OF VARICOSE VEINS
Individuals seeking treatment for varicose veins find
them to be unsightly, but the inquiring physician finds that
nearly all are symptomatic with aching pain, heaviness,
swelling, eczema and itching being the most prominent
symptoms.58 Since reflux at the saphenofemoral junction is
commonly present, the traditional approach to treatment
has been removal of the great saphenous vein after ligation
and division of the saphenofemoral junction.59 Many pa-
tients undergoing the modern surgical approach of proxi-
mal ligation, division, and stripping of the saphenous vein
do so with little downtime, however, some suffer extensive
bruising, hematoma, and pain, especially when large vari-
cose veins have been treated. Furthermore, it is disappoint-
ing that one-third of patients will develop further varicose
veins after such treatment.60
Surgical treatment of varicose veins consists of two
components.61 One is to remove the saphenous vein from
the circulation and the second is to remove varicose veins
from their sources of venous hypertension. The patient’s
perspective is that it is the varicose veins that need treat-
ment. The treating physician’s perspective is similar but he
believes that in order to prevent recurrence, the refluxing
saphenous vein must be removed from the circulation.
Saphenous ablation
Surgical methods of removing the great saphenous vein
from the circulation have included proximal ligation alone,
proximal ligation with ankle to groin stripping, and proxi-
mal ligation with knee to groin stripping. It is generally
agreed that ligation alone, without removal of the saphe-
nous vein, is inadequate62 as the patent vein in the thigh
continues to reflux. The stripping operation has durable
results because the saphenous vein is permanently removed.
The groin dissection itself may have favorable long-term
consequences but its immediate effect is prolonged sore-
ness and tenderness.
Despite the acknowledged limitations of surgery and
the negative patient perception of vein stripping, there are
advantages to operative treatment of varicose veins. The
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done in a well-equipped operating room with effective
anesthesia, all of the pathologic veins can be dealt at one
time. Both saphenous extirpation and phlebectomy can be
done at one sitting with no need for immediate retreat-
ment. There are several modern ways to diminish morbid-
ity,5 but there is always some downtime. Because of this,
attempts have been made to minimize postoperative dis-
comfort and yet maintain the benefits of saphenous vein
extirpation.
Great saphenous vein stripping
Groin-to-knee stripping of the saphenous vein is gen-
erally considered in every patient requiring surgical inter-
vention. Although the decision may be against saphenous
stripping, removal of the varicose clusters via stab avulsion
or some form of sclerotherapy is an absolute requirement in
nearly all patients.
Properly performed preoperative marking serves to
document the extent of varicose vein clusters and identify
the clinical points where control of varices is required. As a
rule, incisions in the groin and at the ankle should be
transverse and placed within skin lines. The groin incision
should be high enough to permit identification of the
saphenofemoral junction. The best cosmetic results in the
thigh and leg are generally obtained with vertical incisions.
Transverse incisions are used in the region of the knee, and
oblique incisions are appropriate over the patella when the
incisions are placed in skin lines.
The practice of identifying and carefully dividing each
of the tributaries to the saphenofemoral junction has been
dominant for over 90 years. The rationale for this has been
the perceived inadvisability of leaving behind a network of
anastomosing inguinal tributaries. The importance of these
efforts has been underscored by descriptions of residual
inguinal networks as an important cause of varicose vein
recurrence.63 However, this central principle of varicose
vein surgery is currently under challenge, on the grounds
that groin dissection can lead to neovascularization and
subsequent recurrence of varicosities.
After exposure of the saphenofemoral junction, a dis-
posable plastic Codman stripper can be introduced from
above downward. Although plastic disposable vein strip-
pers and their metallic equivalents were designed to be used
with various-sized olives to remove the saphenous vein, an
inversion technique in which the vein is tied to the stripper
below its tip, inverted into itself, and removed distally is
more efficient and reduces tissue trauma in the thigh.
Alternatively, an Oesch stripper can be employed.
Passage of the stripper from above downward to the
ankle serves to confirm the absence of functioning valves,
and stripping of the vein from above downward is unlikely
to cause nerve damage. In exposing the saphenous vein at
knee level, the superficial fascia must be incised because the
vein lies between this structure and the deep fascia of the
thigh. If the stripper passes unimpeded to the ankle, it can
be exposed with an exceedingly small skin incision placed in
a carefully chosen skin line. At the ankle, the vein should becarefully dissected to free it from surrounding nerve fibers.
If this is not done, saphenous nerve injury will result, and
the patient will experience numbness of the foot.
Subcutaneous extravasation of blood during and after
saphenous vein stripping is a major cause of discomfort and
occasional permanent skin pigmentation. Use of high vol-
ume, dilute tumescent local anesthesia will minimize ex-
travasation. Applying a hemostatic tourniquet after Esmark
exsanguination of the limb can also minimize such extrav-
asation. If a tourniquet is not used, the entire operation can
be performed with the limb elevated 30 degrees. To de-
crease oozing into the venectomy tract, a 5 cm roller gauze
soaked in a 1% lidocaine-epinephrine solution can be at-
tached to the stripper using the ligature fastening the
saphenous vein to the stripping device. The hemostatic
pack, which lies within the saphenous vein, can be pulled
into the tract with minimum tissue trauma; when it is not
inverted into the vein itself, it can act as an obturator to
facilitate removal of the saphenous vein without tearing. As
the vein is removed by inversion, the gauze is left in place
for hemostasis.
Incisions to remove varicose clusters vary according to
the size of the vein, the thickness of the vein wall, and the
degree of adherence to perivenous tissues. Except in areas
where skin lines are obviously horizontal, vertical incisions
1 to 3mm in length are appropriate and successive incisions
are spaced as widely as possible. Varicosities are exteriorized
by means of hooks or forceps. Dissection of each perforat-
ing vein at the fascial level is not required and may in fact be
cosmetically undesirable. There is no need to ligate or clip
the ends of each varix. The combination of leg elevation,
trauma-induced venospasm, and direct pressure ensures
adequate hemostasis.
Neovascularization after saphenous vein stripping
The advent of minimally invasive techniques, such as
radio-frequency and laser ablation of the great saphenous
vein, has focused attention on neovascularization in the
groin as a potential cause of recurrent varicose veins after
saphenous stripping. Neovascularization is commonly seen
following the traditional stripping procedure64 and is
thought secondary to “frustrated” venous drainage from
the abdominal wall and perineum.65 Regardless of the
mechanism, the result is recurrent reflux in thigh or lower
leg veins.
Although the phenomenon had been previously de-
scribed,66 neovascularization was only a clinical curiosity
until venous ultrasound became widely available for post-
operative surveillance of patients.67 It must now be ac-
cepted that this condition is more common than previously
realized.68 Neovascularization has been demonstrated by a
variety of imaging techniques including phlebography cor-
rosion casts. Histologic study has confirmed that the vessels
seen as regrowth of veins at the saphenofemoral junction
are truly new vessels.69 Many now believe that neovascu-
larization is a major cause of recurrent groin reflux after
varicose vein surgery.70
eratio
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Lower extremity varicose vein disease is most often
associated with truncal venous insufficiency involving the
saphenous system; the great saphenous vein, the small
saphenous vein, and/or incompetent major tributaries or
perforator veins. As discussed above, varicose vein disease
has historically been treated with stripping of the saphenous
vein, and interruption and removal of the major tributary
and perforator veins.71 However, endovenous ablation
procedures have more recently been reported to be safe and
effective methods of eliminating the proximal portion of
the great saphenous vein, the small saphenous vein, and
even tributary and perforator veins from the venous circu-
lation, with faster recovery and better cosmetic results than
stripping.60,72-74 The three currently available methods to
achieve ablation of diseased veins are: the Closure proce-
dure using a radio-frequency (RF) catheter and generator
(VNUS Medical Technologies, Inc, Sunnyvale, Calif); the
endovenous laser ablation procedure using a laser fiber and
generator (various manufacturers); and endovenous chem-
ical ablation with ultrasound guided foam sclerotherapy
(either injected or catheter-directed). The first two meth-
ods use electromagnetic energy to destroy the vein in situ;
the latter utilizes a foamed chemical detergent (Polidocanol
or sodium tetradecylsulfate). As with stripping, portions of
the great and/or small saphenous vein, perforator veins,
and varicose tributaries remaining after these endovenous
procedures must be treated with either injection sclerother-
apy or phlebectomy.
Endovenous thermal ablation
Prolonged exposure of tissues to high frequency energy
results in total loss of architecture with disintegration and
carbonization. Clinical observation suggests that these
minimally invasive procedures do destroy the saphenous
vein and ultimate results are quite acceptable and compa-
rable to stripping of the saphenous vein. However, patients
experience minimal discomfort and time lost from work.
Clinical trials evaluating RF ablation of the great saphe-
nous vein have demonstrated success rates equivalent to or
better than historical results for stripping.73,75 These find-
ings were confirmed in a prospective, randomized study
comparing RF ablation with stripping.76 Several reports,
some with follow-up as long as 5 years, have confirmed the
safety and efficacy of RF saphenous vein ablation65,77 (Ta-
ble IV). Ablation rates of 90% or more have been routinely
Table IV. Efficacy of VNUS closure of the saphenous vein
1-year 2-y
Number 458 2
Reflux free 90% 88
Varicose vein recurrence 14% 16
Adapted from Merchant RF, DePalma RG, Kabnick LS. Endovascular oblit
VNUS Medical Technologies, Inc, San Jose, Calif.demonstrated.78Following the introduction of RF ablation, reports
appeared demonstrating an unprecedented rate of success-
ful great saphenous vein ablation using laser energy.79 The
original clinical trials, and 3-year follow-up data, confirm
the high success rate reported earlier.80,81 Other centers
have similarly reported high rates of successful ablation.74
The details of heat ablation of the truncal veins have
been described elsewhere.65 In brief, after ultrasound local-
ization of the truncal vein, it is accessed either directly
through a micro incision or percutaneously under ultra-
sound guidance, at a suitable site near the knee or higher. A
sheath followed by the RF catheter or laser fiber are inserted
into the truncal vein and advanced to the most superior
point of treatment. Following injection of ultrasound
guided, dilute local anesthetic into the saphenous sheath,
the generator is activated and the vein is ablated during
withdrawal of the catheter/fiber.
Patient selection
Inclusion criteria should include: symptoms and phys-
ical signs of venous insufficiency; duplex ultrasonography,
performed by a fully qualified sonographer, documenting a
patent vein with reflux greater than 0.5 seconds; patent
deep venous system; vein conducive to catheterization; and
full patient mobility. Exclusion criteria include arterio-
venous malformations; restricted ambulation; and deep
venous obstruction. As a practitioner’s experience with
endovenous ablation expands, relative exclusion criteria
may be relaxed, and patients with deep venous reflux,
previous venous treatment, large diameter veins, or those
on chronic anticoagulant therapy or hormone replacement
therapy may be safely and successfully treated.
Complications
Intraoperative and postoperative complications occur
infrequently, and are generally well tolerated and short-
lived. Intraoperative complications include: difficult device
access or advancement and treatment interruption (RF
only). Postoperatively, patients may encounter bruising
and pain (more often with laser);82 paresthesia; thermal
skin damage; superficial thrombophlebitis; lymphedema;
andDVT. The risk of themost clinically significant of these,
DVT, is generally reported to be less than 1%,78 usually in
calf veins. Paresthesias have been reported in 2% to 16% of
patients following RF ablation and are usually transitory.83
3-year 4-year 5-year
119 107 37
87% 87% 84%
14% 21% 22%
n of saphenous reflux: a multicenter study. J Vasc Surg 2002;35:1190-6. 77ear
40
%
%In a report of patients followed carefully in one center, the
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with laser and RF ablation.84
Notably, as discussed above, there is a relative absence
of neovascularization after thermal ablation of the great
saphenous vein.77 Endovenous ablation of the great saphe-
nous vein deliberately leaves the superficial epigastric vein
intact, which, it is believed, has resulted in few reports of
neovascularization at the 5-year interval.
Follow-up
The risk of incomplete ablation and recanalization of
the treated vein as well as the need for adjunctive treatment
of the distal great saphenous vein, refluxing tributaries, and
small saphenous vein mandate careful follow-up after vein
ablation. Color-flow Doppler ultrasound, interviews, and
physical examinations at appropriate intervals are needed to
achieve successful treatment. It is not appropriate to merely
ablate the proximal vein and expect the patient’s symptoms
and varicosities to resolve. Unless one is committed to
careful follow-up and adjunctive treatment, the practitioner
and the patient will be left with unsatisfactory results.
There is considerable confusion in the literature regard-
ing the definition of successful treatment, the means used
to detect treatment failures, and the reporting of results.
Recent advancements in ultrasound technology have al-
lowed more critical evaluation of clinical results than were
possible in the past. Duplex examination after vein ablation
should include grey-scale, compression, and color flow
Doppler modalities. Identification of treatment failure is
dependent on the sensitivity of the ultrasound equipment
used, the expertise of the sonographer, and the vigor with
which the examination is conducted.
The development of foam sclerotherapy has further
called into question even the most critical examination
techniques. Because foam is an excellent ultrasound con-
trast medium, injection into distal vein segments, tributar-
ies, and incompetent perforators will sometimes reveal an
incompletely treated vein that is occluded by all other
duplex criteria. Whether these minimally patent segments
will become clinically significant is currently unknown.
However, patients complaining of localized pain in the area
of a previously ablated vein deserve very careful examina-
tion to identify incompletely ablated segments.
It has been reported that most incompletely ablated
veins will be seen in the first few months after treatment.80
However, patients with recurrent symptoms and partially
patent segments have been identified more than 3 years
following apparently successful ablation. Thus, it is neces-
sary to perform careful follow-up of these patients for 1
year, and then yearly, or certainly when recurrent symp-
toms occur.
CONCLUSIONS
Endovenous ablation is generally safe. Intraoperative
and postoperative complications are infrequent and gener-
ally less morbid than with traditional surgical procedures.
Differences in methods of follow-up and definitions of
successful ablation may explain differences in results be-tween published reports. Only long-term follow-up will
demonstrate where these minimally invasive methods be-
long in the therapeutic armamentarium of the treatment of
chronic venous disease of the lower extremity. While some
surgeons have expressed the view that none of these tech-
niques have yet been shown to better conventional surgery
in the long term, the patient’s perception has uniformly
been that minimal invasion is better.
Sclerotherapy of Varicose Veins
Sclerotherapy is a well-accepted treatmentmodality not
only for varicose veins of the lower or upper extremities, but
also for vascular malformations such as small hemangiomas
and varicose veins associated with the Klippel-Trenaunay
syndrome, where surgery may not be indicated. Sclerother-
apy is considered the treatment of choice for cosmetic
nuisances such as spider veins or telangiectasias and venous
lakes. Advances in imaging technology have also extended
the use of sclerotherapy to treatment of reflux in areas such
as the saphenofemoral and saphenopopliteal junctions.
Some of the “new” techniques are being evaluated and
more representative results should become available within
a few years.
Clinical evaluation
After the initial interview, physical examination deter-
mines the type of varicose veins and the most appropriate
type of treatment. An extensive noninvasive evaluation is
not required in patients withmild telangiectasias. However,
the durability of sclerotherapy in the presence of severe
reflux is often limited and patients with more extensive
disease require an assessment of deep and superficial reflux
with Doppler and duplex ultrasound examinations.
Indications for sclerotherapy
Sclerotherapy is clearly indicated in the following situ-
ations: Telangiectasias and venous lakes, usually 1 mm or
less in diameter; varicosities between 1 to 3mm in diameter
without connection to refluxing main trunks; residual or
recurrent varicosities without obvious connection to in-
competent main venous trunks; congenital malformations
of venous predominance such as small hemangiomas; and
some diffuse congenital malformations where surgery is
contraindicated. Hemorrhage due to variceal rupture can
also be effectively treated with sclerotherapy. Sclerotherapy
may also enhance the venous ulcer healing in some situa-
tions. This is a temporary measure while definitive treat-
ment is planned. Finally, the introduction of foam sclero-
therapy has widened the indications for sclerotherapy to
include themain great and small saphenous trunks, varicose
tributaries, and perforating veins.
Sclerotherapy is not indicated in elderly and sedentary
patients afflicted by arthritis or medical conditions that
prevent active mobilization. Relative contraindications may
include the presence of severe systemic diseases such as
diabetes, cardiac or renal insufficiency, emphysema, colla-
gen diseases, and malignancies; arterial insufficiency docu-
mented by an ankle brachial index below 0.7; a history of
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anaphylaxis; a body surface index 26 where compression
is difficult to apply; and the use of anticoagulants, which
may be associated with a risk of large hematomas or ecchy-
mosis.
Sclerosants
Sclerosants are classified according to their mode of
action as osmotic agents, detergents and chemical or cor-
rosive agents. Osmotic agents include hypertonic sodium
chloride (23.4%), 65% glucose and sodium salicylate; the
detergent agents are sodium tetradecyl sulfate, polidocanol
and sodium morrhuate; and corrosive or chemical sclero-
sants include sodium and potassium iodide, chromglycer-
ine, and absolute alcohol. Only the detergent agents, so-
dium tetradecyl sulfate, sodium morrhuate, and
ethanolamine oleate are approved by the United States
Food and Drug Administration. The most commonly uti-
lized agents in this country are sodium tetradecyl sulfate
and hypertonic sodium chloride (the latter not FDA ap-
proved as a sclerosant).
All currently available sclerosants cause irreversible mo-
lecular damage to the venous wall, permanently deactivat-
ing the vein and producing a destructive endosclerosis.
They specifically affect lipids on the endothelial cell surface,
softening the endothelium and causing the endothelial cells
to detach and fall apart in plaques. Deeper layers, including
the media, are affected and spasm is regularly seen with
ultrasound during treatment. Few severe side effects have
been reported with foam sclerotherapy, but local side ef-
fects, including hyperpigmentation and mild superficial
thrombophlebitis may occur.
Sclerosant concentration depends on the size of vein to
be treated. In general, dilute sclerosants are used for small
veins and higher concentrations for larger veins. Telangiec-
tasias (1 mm or less) are usually treated by injecting 0.125%
to 0.25% sodium tetradecyl sulfate or 0.5% polidocanol.
Veins 3 to 6 mm respond well to 0.5% to 0.75% sodium
tetradecyl sulfate or 0.75% to 1.0% polidocanol. Veins
larger than 6 mm diameter require 3.0% sodium tetradecyl
sulfate or 2.0% to 3.0% polidocanol.85
Foam sclerotherapy
The liquid form of sclerotherapy was universally used in
the past. The “air-block” technique86 has been used in
small venules, where displacement of the blood column by
microbubbles can be observed. This method was modified
by Cabrera87 to produce a thicker, larger mass of sclero-
foam. The action of foam sclerosant differs from that of the
liquid; foam forming a coherent mass that displaces the
blood column and allowing controlled, prolonged contact
with the venous endothelium. The development of foam
sclerotherapy has extended its utility to include the ultra-
sound-guided treatment of large venous trunks and bulky,
deeply seated congenital vascular malformations of venous
predominance.
Only detergent based sclerosants, such as polidocanol
and sodium tetradecyl sulfate, can be used as a foam.Sclerofoam is produced by mixture of a well-tolerated,
physiologic gas and a relatively small amount of the deter-
gent sclerosant. Oxygen, CO2, and room air have all been
successfully utilized. Althoughmanymethods of producing
foam have been described, the easiest may be that reported
by Tessari, using two syringes connected by a three-way
stopcock.69 Two syringes are connected by a three-way
stopcock, creating foam by alternatively moving the syringe
pistons up and down. Such foam persists for a few minutes
and can be injected into tributary varicosities and the
saphenous veins. Depending on the vein size, Frullini88
recommends total volumes of 3 to 5 mL of 1% to 1.5%
sodium tetradecyl sulfate or 2% to 3% polidocanol. Telan-
giectasias are successfully treated with 0.10% to 0.25%
polidocanol foam. The higher concentrations are used for
large truncal veins less than 9 mm in diameter. In treating
the saphenous trunks, sclerosing foam may be directly
injected or delivered by means of an indwelling catheter,
sometimes with an occlusive balloon just below the saphe-
nofemoral junction. Others have described duplex con-
trolled catheter injection of sclerosing foam in a bloodless
field using controlled-ischemia.89
Ultrasound guided foam sclerotherapy for saphenous
trunks with patent deep venous junctions remains investi-
gational in the U.S., although clinical trials are either in
progress or planned for the near future. However, numer-
ous reports from Europe have demonstrated excellent re-
sults using foam sclerosants for ablation of the saphenous
veins.72 Successful ablation has been reported in greater
than 90% of patients.90 Others have shown long-term (5
years) fibrosis in up to 81% of treated veins. A 98% rate of
great saphenous occlusion was reported in 65 extremities
followed for up to 31 months using the bloodless field
technique described by Trinidad.89
Despite the promise of foam sclerotherapy, previous
experience with liquid sclerosants must be kept in mind
when treating the junctions. Waugh91 reported recurrence
rates of nearly 60% at 5 years using sclerotherapy either
alone or in combination with high ligation for the treat-
ment of primary varicose veins. In themodern era, random-
ized studies performed from England, Sweden, and North
America have documented that “liquid sclerotherapy”,
used as a single form of treatment, for all types of varicose
veins has a very high incidence of recurrence.92,93 The
introduction of these new techniques has opened new
avenues of investigation. Careful evaluation and large ran-
domized trials comparing liquid vs foam sclerotherapy with
and without saphenous ablation will provide new insights
into the true value of sclerotherapy as a method of treat-
ment for varicose veins.
Consensus recommendations
Consensus recommendations regarding foam sclero-
therapy were generated during the Second International
European Symposium on Sclerotherapy.94 The following is
a summary of the consensus conclusions.
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liquid sclerotherapy are similar. However, thicker foam
is recommended for large veins and thinner, less viscous
foam for smaller veins. The Monfreux method95 pro-
duces thicker foam than Tessari’s or Cabrera’s. Possible
new indications for sclerofoam are: pelvic varices, vari-
cocele, hydrocele, venous angiodysplasias, and Baker
cysts. Patients should be well informed of the advan-
tages, limitations and complications of foam sclerother-
apy.
2. An important advantage of sclerofoam is its echogenic-
ity. Duplex ultrasound control of the procedure is par-
ticularly important when treating large veins, perfora-
tors, veins in the flexion (knee, groin) areas, and
recurrent varices. Catheter control sclerofoam tech-
niques may improve the safety and effectiveness of the
procedure.
3. The majority of participants recommended elevation of
the extremity during treatment and avoiding the erect
position shortly after the procedure.
4. The effects of sclerofoam at a given concentration are
greater than for liquid sclerotherapy (contact of the
agent is direct and more prolonged that with the liquid
form). It was recommended that in C-1 varices (reticu-
lar veins and telangiectasias) be treated with a maximum
of 0.5 mL of foam per site and a total volume of 6 to 8
mL using the Tessari method. Some participants have
used up to 14 mL of foam per session. For C-2 varices,
a maximum volume of 6 to 8mL of 3% polidocanol per
session, prepared by the Monfreux method, was recom-
mended. The majority of participants recommended
beginning with the most proximal point of insufficiency
and proceeding downwards to the distal varicosities.
5. The indications for compression are similar for liquid
and foam sclerotherapy. Compression of telangiectasias
is controversial. In larger veins, compression should be
applied for a week or longer.
SURGICAL REPAIR OF INCOMPETENT
VENOUS VALVES
Surgical repair of incompetent venous valves is a clini-
cally effective procedure with several series reporting 65%
to 80% actuarial healing of stasis ulcers at 5 years and some
even at 15 to 20 years.96-109 Yet, it has remained the niche
of only a small coterie, likely due to a very steep learning
curve, lack of the dedicated resources required for the
comprehensive management of venous disease, and indif-
ference by most training programs. The scientific validity of
the procedure has been questioned as well; the best evi-
dence coming from non-randomized series of selected pa-
tients. However, many currently effective surgical proce-
dures are based on similar evidence. As for other such
procedures, case selection is the key to successful outcomes.
Despite its utility, the advent of venous stent technol-
ogy is likely to further diminish the use of deep venous
reconstruction. About two thirds of patients with venous
stasis ulceration heal their ulcers following stent placement;
a much easier, minimally invasive procedure likely to enjoywidespread adoption. Yet a third of the cases, still a very
large number in absolute terms, will have recalcitrant ulcers
and be candidates for valve reconstruction. Reconstruction
is certainly an attractive alternative to life long Unna boot
regimens.
Reflux and venous stasis
Venous skin changes in general and venous ulceration in
particular are traditionally attributed to reflux rather than
obstruction. However, the experience with venous stents
clearly demonstrates that the pathogenesis involves a poorly
understood, complex interaction between reflux and obstruc-
tion.101 Although the vast majority of post-thrombotic cases
involve both obstruction and reflux, the frequent presence of
May-Thurner type obstructive lesions in “primary” disease has
only recently been recognized. In such cases, symptoms may
improve following stent placement alone without correction
of the reflux component. Raju andNeglen have hypothesized
that the obstructive lesion is an often silent, permissive condi-
tion predisposing to symptoms once additional pathology
such as reflux develops.101 In common with other well known
permissive conditions such as hyperacidity and peptic ulcer,
obesity and diabetes, correction of the permissive condition
alone is often curative.
Measurement of reflux
Venous filling time (VFT) determined by ambulatory
venous pressure measurement and the venous filling index
(VFI90) measured by air plethysmography are reliable
quantitative global indices of venous function of which
reflux is a dominant and reversible component.96 Improve-
ments in VFT andVFI90 have been documented after valve
reconstruction. VFT improves by at least 4 seconds, often
more, but seldom normalizes following valve reconstruc-
tion. This is partly due to the multiple factors that deter-
mine ambulatory venous pressure and the outstation nature
of valve reflux. Ulcers will fail to heal if VFT persists below
5 seconds following valve repair.
Duplex has replaced descending venography as the
preferred technique to identify reflux at specific sites and
has the potential to be used quantitatively. As of now, it is
only qualitative.100 Initial enthusiasm for valve closure time
to quantify reflux has proved disappointing. A related pa-
rameter, calculation of reflux volume has proved unreliable
as well. Peak reflux velocity has been shown to be of value
statistically, but the variance is such that it is not clinically
useful.
Unfortunately, there is still no reliable quantitative
measure to guide the optimal site for valve repair; to prior-
itize the relative importance of superficial, perforator and
deep interventions; or to assess outcome. For this reason,
controversy regarding the optimal valve site for repair (fem-
oral vs popliteal “gatekeeper”) still persists. Raju prefers the
femoral site only because it is technically easier. Fortu-
nately, venous reflux, as most venous pathologies, responds
clinically to partial correction at least in the short term.
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The oldest and most durable repair in ultrasound
terms, is internal valvuloplasty.98,99,102 External and trans-
mural techniques are faster, allowing multiple single stage
valve reconstructions, and can be used even in smaller
caliber veins.103 The latter techniques deteriorate faster in
duplex terms but this is not reflected in clinical outcome.
All techniques, including the internal valvuloplasty, show
alarming degrees of deterioration by ultrasound.106 The
cause of such deterioration remains unknown. There is no
clinical evidence that multiple valve reconstructions are
better than single repairs in “primary” disease.
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